Shining a light on the oncology portfolio
Imperial Innovations diversified investment portfolio includes seven unquoted oncology-focused companies (excluding the recently announced Artios Pharma), which represent 20% (72m) of total portfolio value. These companies (six in therapeutics, one in medtech) are focused on improving cancer care through the development of proprietary technology platforms, therapeutics and diagnostics. The size of recent funding rounds led by Innovations points to the increasing momentum in and maturity of this portfolio segment and, with several important milestones approaching in the near to mid-term, there is significant potential for value creation. This report profiles these seven companies, including their technology approach and upcoming catalysts.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.